Abiopharma

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

Meet the New Chase Sapphire Preferred: Earn More Than Ever, Same $95 Annual Fee

Rubrik’s “To Catch a Thief” by Nicole Perlroth Wins a Tribeca X Award for Best Audio/Podcast

BrightSpire Capital Announces $0.16 Per Share Dividend for Second Quarter 2026

NexPoint Diversified Real Estate Trust Announces Investor Update Call

Celanese and Siegwerk Collaborate to Advance More Sustainable Printing Ink Solutions with Bio-Based Ethyl Acetate

Principal Asset Management® Launches Fixed Income ETF Suite

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active